KEYNOTE-859: KEYTRUDA® (pembrolizumab) plus chemotherapy for the first line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

Please refer to the KEYTRUDA Summary of Product Characteristics and Risk Minimisation Materials before prescribing KEYTRUDA. Risk Minimisation Materials are available online, from your MSD representative or from MSD Medical Information (Email: medicalinformationuk@msd.com, Phone: 0208 154 8000).

Supporting documentation

Prescribing Information [External link]
By clicking the link above you will leave the MSD Connect website and be taken to the emc PI portal website.

KEYNOTE-859: KEYTRUDA® (pembrolizumab) plus chemotherapy for the first line treatment of locally advanced unresectable or metastatic HER2-negative gastric or gastro-oesophageal junction adenocarcinoma

Supporting documentation

For UK Healthcare Professionals